| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | - |
| Drug | Abatacept |
| Brand | Orencia® |
| Indication | In combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a tumour necrosis factor (TNF)-alpha inhibitor. |
| Assessment Process | |
| Rapid review commissioned | 28/11/2012 |
| Rapid review completed | 21/12/2012 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
| Full submission received from Applicant | 02/07/2013 |
| NCPE assessment completed | 11/11/2013 |
| NCPE assessment outcome | Reimbursement not recommended at the submitted price |
November 2015
The HSE has approved reimbursement following confidential pricing negotiations.
